Confidentiality first
Discretion isn't a feature, it's the foundation. Identities and details stay protected until both sides agree to proceed.
About ANDA Exchange
We built the marketplace this industry was missing.
ANDA Exchange, LLC is a U.S. company dedicated to one thing: helping pharmaceutical companies buy and sell Abbreviated New Drug Applications efficiently, confidentially, and at fair value.
Our Story
A specialist solution to a stubborn problem.
Across the generic industry, valuable ANDAs sit dormant — discontinued, acquired-and-shelved, or simply never marketed. For the companies holding them, they're an afterthought. For the right manufacturer, they're a ready-made route into a market.
The trouble has always been connecting the two. There was no efficient, discreet way to match an idle application with a motivated buyer — and no specialist to handle the valuation, negotiation, and diligence in between.
ANDA Exchange was created to be exactly that: a focused marketplace and a hands-on team, turning forgotten applications into closed transactions.
- U.S.
Based company serving a global pharmaceutical client base
- 5,000+
Prospective buyers in our relationship network
- ANDAs only
A single, specialized focus — not a side business
How We Work
Principles that make a confidential market function.
Aligned incentives
We're paid on success. Our interests sit squarely with the seller's — the best outcome for you is the best outcome for us.
Genuine expertise
We speak the language of dossiers, FDA status, and generic economics, so nothing gets lost in translation.
Our Team
The people behind the deals.
Decades of combined experience across pharmaceutical licensing, business development, and generic dealmaking.
Rob Camerer
Chief Executive Officer
BS Chemistry · BS Chemical Engineering · MBA International Studies
Founded the company in 2006. 36 years of experience across Specialty Pharma, Rare Diseases, Complex Injectables, Biologicals, Peptides, and Small Molecules.
Dr. Gopal Venkatesan
Group President
B.Pharm Sci · MBA, University of Bombay · Executive Program, Harvard Business School
Nearly 38 years in global pharmaceuticals and bio-pharmaceuticals across India and the U.S. Most recently President of Wockhardt's US business, with two decades creating and acquiring product portfolios — first-to-market products, complex generics, biosimilars, and novel products.
Jonathan Camerer
Executive Vice President
Bachelors in Marketing Management
More than 15 years managing relationships in the generic pharmaceutical industry. A collaborative, results-driven approach has built lasting partnerships founded on trust, responsiveness, and shared success.
Joshua Camerer
Business Development Manager
Bachelors in Administrative Management
Extensive experience in forecasting and statistical data analytics in pharma, bringing a data-driven approach to financial strategy. A background in healthcare software — building financial systems for post-acute care — sharpened his expertise turning complex data into strategic decisions.
Let's talk about your portfolio.
Whether you're holding idle ANDAs or hunting for your next market, we'd like to hear from you.